Dose escalation has commonly been observed as a treatment strategy, even beyond regulatory recommendations, to achieve and maintain response, with average rates of dose escalation estimated at 30–36% in IBD patients over 1 year with anti-TNF-α or anti-integrin agents [10,11]. This evidence concerns the gene TNF and inflammatory bowel disease.